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429In vitro induction of ALP levels predicts in vivo bone forming capacity of human BMSCs(ALP) mRNA levels and ALP activity during in vitro osteogenic differentiation. The predictive value of in vitro ALP induction was
confirmed by analyzing “bulk-cultured” BMSCs from various bone marrow biopsies. Our findings show that in BMSCs, the
additional increase in ALP levels over basal levels during in vitro osteogenic differentiation is predictive of in vivo performance.
© 2013 Elsevier B.V. All rights reserved.Introduction
Stem cells within the bone marrow stromal cell (BMSC)
population have the capacity to form bone, cartilage,
stroma and fat, and are present at frequency between
0.01% and 0.001%. These non-hematopoietic stem cells in
the BM were first described by Friedenstein as colony-
forming-units-fibroblasts (CFU-Fs) and its progeny of plastic
adherent multipotent cells as BMSCs (Friedenstein et al.,
1968, 1974, 1976). Not only the multipotency, but also the
heterogeneity of BMSC clones was shown in 1997 by
Kuznetsov et al. (1997). The lineages of differentiation of
BMSCs and the methods to expand BMSCs ex vivo, including
clinically approved expansion protocols, have increased in
the last four decades (Pittenger et al., 1999) (Jiang et al.,
2002) (Kolf et al., 2007) (Phinney and Prockop, 2007) (Seshi
et al., 2000) (Liu et al., 2005) (Quirici et al., 2002) (Gentry
et al., 2007) (Leyva-Leyva et al., 2013) (Buhring et al., 2007)
(Chung et al., 2013) (Gang et al., 2007) (Simmons and Torok-
Storb, 1991). The International Society for Cellular Therapy
has described minimal criteria to define multipotent BMSCs
in an attempt to foster a more uniform characterization
(Dominici et al., 2006). However, there is compelling evidence
that BMSCs are amixture of cells that can differ not only in size
and morphology but also in proliferation rates and in vitro
differentiation capacity (Kuznetsov et al., 1997; Satomura et
al., 1998). Although a large number of cell surface markers
show consistent and homogeneous expression on all BMSCs in
culture, large variation is observed in the expression of newly
identified markers and the question arises as to whether this
relates to donor-to-donor variation or heterogeneity in the
expanded BMSC cultures (Dominici et al., 2009) (Sarugaser et
al., 2009) (Lee et al., 2010) (Russell et al., 2010). Observations
concerning heterogeneity have mostly been reported for in
vitro studies, but little is known about how this translates into
differences in outcome when BMSCs are used for in vivo
applications.
BMSCs hold great promise for use in cell-based bone tissue
engineering. In a previous study, we showed that by subs-
tituting human platelet lysate (PL) for fetal bovine serum
(FBS), we could generate bone from 9 out of 9 for PL and in 6
out of 9 for FBS cultured donors in an in vivo ectopic murine
bone formation model. However, the amount of bone that
was produced by the various BMSC preparations demonstrat-
ed a large variation (Prins et al., 2009), as was consistent
with the observations of other groups (Kuznetsov et al., 1997)
(Digirolamo et al., 1999) (Mendes et al., 2002) (Siddappa et al.,
2007) (Siddappa et al., 2008) (Agata et al., 2010). Although
density dependent cells are present in initial BM cultures,
total BMSC cultures are mainly the result of expansion of cells
that formed the initial colony that was started from the
adherent cells with clonogenic potential also referred to as
colony forming unit-fibroblast (CFU-F). After passaging of the
initial cultures, the cultures will mainly consist of cells withthe highest replating potential. The final total culture will
only result in balanced cell product if the original CFU-Fs have
similar rates of proliferation and similar differentiation
potential. Heterogeneity in these characteristics will result
in great heterogeneity in the end product. This requires the
definition of predictive parameters to determine whether the
cultured BMSCs meet the requirements for their intended use.
The aim of the current study was to obtain greater insight
in the heterogeneity of clonal populations that contributes
to a BMSC culture with the goal of correlating in vivo bone
forming capacity with in vitro predictors. We therefore
expanded single CFU-F-derived strains using PL and deter-
mined the in vivo bone forming capacity of the subsequent
clonal BMSC cultures and correlated this to the cumulative
total cell production, to the in vitro differentiation capacity
towards adipocytes, chondrocytes, osteoblasts, and to the
cell surface marker expression using a large panel of mono-
clonal antibodies (mAbs). Our data demonstrate that clonal
BMSC cultures differ considerably in these characteristics
which are reflected in the heterogeneity within the total BMSC
population. We could demonstrate that in vivo bone forming
capacity of the clonal BMSC strains can be predicted by the
magnitude of induction of alkaline phosphatase (ALP) during
the in vitro osteogenic differentiation process. This was
confirmed in non-clonal total BMSC cultures derived from BM
biopsies from various donors. This finding could be beneficial
for the selection of BMSCs with bone forming capacity.Materials and methods
Bone marrow stromal cell expansion
Human BM aspirates were obtained from the iliac crest
during standard hip operations or BM stem cell harvest
procedures from donors that had given written informed
consent. The single cell-derived BMSC strains were generat-
ed from a BM aspirate collected from an 11-year old patient
for routine diagnostic purposes, as approved by the institu-
tional medical ethics committee. The BM aspirate was
filtered through a 70 μm nylon cell strainer to remove cell
aggregates and fragments of bone. Mononuclear cells (MNCs)
were isolated by density gradient centrifugation (Ficoll
1.077 g/cm3). To obtain single cell-derived BMSC strains
seven 96-wells plates were seeded with 10,000 MNCs per
well. Cells were cultured in α-minimal essential medium
supplemented with 100 U/ml penicillin and 100 μg/ml
streptomycin (Life Technologies), 10 U/ml heparin. For
growth stimulation we added 5% human platelet lysate
(PL), which was refreshed every three or four days as
previously described (Prins et al., 2009) and maintained at
37 ºC and 5% CO2. After 2 weeks, fifty single CFU-F-derived
colonies were expanded using PL supplemented medium
and tested for their expansion capacity by measuring the
Table 1 mRNA levels of osteogenic markers. The changes of
mRNA levels of multiple genes that are considered as markers
for osteogenic differentiation were analyzed by quantitative
polymerase chain reaction. We determined the utility of the
increase in expression of these marker genes as a prognostic
indicator for in vivo bone forming capacity by a Receiver
Operating Characteristic (ROC) curve. Using the ROC analysis
we calculated the area under the curve (AUC). The p value
indicates the statistical significance to distinguish between
clones with in vivo bone forming capacity and clones without
in vivo bone forming capacity.
Marker AUC p value
Alkaline phosphatase 0.95 0.005
Runx2 0.80 0.06
Bone sialoprotein 0.78 0.08
Osteocalcin 0.76 0.10
Collagen type Iα1 0.71 0.19
Osteopontin 0.69 0.23
Osteonectin 0.60 0.53
430 H-J. Prins et al.cumulative cell counts as well as the production of colonies
weekly (secondary colony forming efficiency).
Colony forming efficiency assay
Cells were seeded in a colony forming efficiency (CFE) assay
as described previously (Prins et al., 2009). In brief, BMSCs
from primary cultures were trypsinized and seeded in 6-wells
plates at 3000; 1000 and 333 cells, per well in duplicate
to generate secondary colonies. Secondary colonies were
trypsinized and seeded to generate tertiary colonies. Ten
days after seeding, colonies were fixedwith ice-coldmethanol
for 15 min and stained with 1:8 in distilled H2O diluted Giemsa
stain (Sigma-Aldrich) for 15 min at room temperature (RT).
The number of colonies, consisting of more than 50 cells, was
scored using an inverted microscope (Zeiss). The calculated
cumulative colony production was determined by multiplying
the cumulative cell number with the observed colony
frequency.
In vivo bone formation in a murine ectopic bone
formation model
To evaluate the in vivo bone forming capacity of each clonal
strain that we generated, we used an ectopic bone-forming
mouse model as previously described (Alves et al., 2013;
Groen et al., 2012; Prins et al., 2009; Siddappa et al., 2007,
2008) with the only modification that for this study,
eighteen immunodeficient RAG-2−/− γc−/− Balb/c mice
were used instead of nude mice. For each clonal strain six
hybrid constructs, consisting of 2 × 105 BMSCs seeded onto
three 2–3 mm biphasic calcium phosphate (BCP) particles,
were implanted in six individual mice. BCP particles were
obtained from Xpand Biotechnology and consist of biphasic
60% hydroxyapatite/40% β-tricalcium phosphate (Yuan et
al., 2002). Experiments were conducted after acquiring
permission of the local Ethical Committee for Animal
Experimentation and in accordance with the Dutch law on
animal experimentation. After six weeks, the mice were
euthanized, the constructs were retrieved from the mice
and evaluated for bone formation by determining the
percentage of bone area in the available pore space as
previously described (Prins et al., 2009).
Osteogenic differentiation and alkaline phosphatase
measurement
To obtain quantitative ALP activity measurements, the
BMSCs were seeded in triplicate at 2 × 104 cells per well in
a 24-wells plate (Nunc). After 24 h, medium was replaced by
NH OsteoDiff medium (Miltenyi Biotec) and cultured for 7
and 11 days, respectively. For a reference value one plate
was fixed at day 1. At the end of the culture period, cells
were fixed with 4% formalin for 15 min at RT, and washed
twice with PBS. Osteogenic commitment was quantified by
staining the cells for ALP using a fluorescent ALP substrate
kit (Vector Laboratories), according to the manufacturer's
protocol. Briefly, the cells were stained with Vector® Red
substrate working solution for 1 h at RT in the dark and
washed with PBS. The nuclei were counterstained with
4′,6-diamidino-2-phenylindole (DAPI; 1:10,000 in PBS) for15 min at RT. After another wash with PBS, plates were
scanned using the Thermo Scientific Cellomics® ArrayScan®
VTI. Per well, a maximumof 20 scanned fields or aminimum of
10,000 objects, using a 10× objective, were analyzed. For the
analysis vHCS™:View software (both from Thermo Fisher) was
used to determine the average ALP intensity per DAPI positive
cell. ALP measurements were normalized to the reference
plate of day 1 and expressed as the ALP fold induction.qRT-PCR for osteogenic gene expression
mRNA levels of osteogenic markers (Table 1) were deter-
mined using quantitative real time polymerase chain
reactions (qPCR) during osteogenic differentiation. BMSCs
were seeded at 1 × 105 cells per well in a 6-wells plate and
cultured in NH OsteoDiff medium (Miltenyi Biotec) for 7 and
11 days, respectively. Reference samples were collected at
day 1. RNA was isolated from cell lysates by using TRIzol
according to manufacturer's protocol (Life Technologies).
RNA was DNase I treated and prepared by using QIAGEN
RNAse-free DNA Set and RNeasy kit (QIAGEN Corp.). The RNA
isolates were verified at 1:50 dilution for purity and quantity
by spectrophotometry at 260 nm and 280 nm, followed
immediately by cDNA synthesis using 0.5 μg of RNA and
Bio-Rad iScript according to manufacturer's protocol (Bio-
Rad Laboratories). A 1:50 dilution of cDNA was used for
amplification. qPCR was performed on a Light Cycler real
time PCR machine (Bio-Rad) using SYBR green I master mix
(Bio-Rad). Gene expression was calculated relative to GAPDH
levels by the comparative ΔCT values method and fold
induction was calculated by normalizing the data to the
values at day 1. The following primers were used: GAPDH
(NM_002046.4) 5′-aaatcccatcaccatcttccaggagc-3′ and 5′-cat
ggttcacacccatgacgaaca-3′; Osteocalcin (NM_199173.4) 5′-gg
cagcgaggtagtgaagag-3′ and 5′-gatgtggtcagccaactcgt-3′; Osteo-
pontin (NM_001040058.1) 5′-ccaagtaagtccaacgaaagc-3′ and
5′-gcatcagggtactggatgtc-3′; ALP (NM_00478.4) 5′-acaagca
ctcccacttcatctgga-3′ and 5′-tcacgttgttcctgttcagctcgt-3′;
431In vitro induction of ALP levels predicts in vivo bone forming capacity of human BMSCsCol1a1(NM_000088.3) 5′-agggccaagacgaagacatc-3′ and 5′-a
gatcacgtcatcgcacaaca-3′; Bone sialoprotein (NM_004967.3)
5′-tccagttcagggcagtagtg-3′ and 5′-accctgtgccaggcgtgg-3′;
Runx2 (NM_001024630.3) 5′ tccggaatgcctctgctgttatga 3′ and
5′-aaggtgaaactcttgcctcgtcca-3′; Osteonectin (NM_003118.3)
5′ cagcaccccattgacgggt 3′ and 5′-gagagaatccggtactgtgg-3′.
Adipogenic differentiation
Differentiation of the cells towards the adipogenic lineage was
induced by incubating the cells in adipogenic differentiation
medium as previously described (Pittenger et al., 1999). In
short, cells were seeded in triplicate into a 24-wells plates
(Nalgene Nunc) at a concentration of 2 × 104 cells per well.
After 24 h, the medium was replaced by adipogenic induction
medium (MDI). The medium contained high glucose Dulbecco's
Modified Eagle's Medium (DMEM) (Invitrogen), 10% Hyclone
fetal bovine serum (FBS), 0.1 μM dexamethasone, 0.5 μM
isobutyl methyl xanthine, 10 μg/ml insulin and 100 μM
indomethacin (all from Sigma-Aldrich). After 2 days, the
medium was changed to adipogenic maintenance medium
(AM), consisting of DMEM, 10% FBS, and 10 μg/ml insulin and
incubated for 24 h, subsequently incubated in MDI medium
and medium was changed every 2 days for 4 days, and finally
for 1 week in AM medium. Adipogenic differentiation was
evaluated qualitatively on the basis of the morphological
appearance of stained Oil Red O lipid droplets as previously
described (Prins et al., 2009). To quantify the amount of lipid
droplets formed, cells were fixed with 10% paraformaldehyde,
and stained using fluorescent Nile Red O (Sigma-Aldrich). Cells
were washed twice with PBS and incubated for 5 min with
a solution containing DAPI and 0.5 μg/ml Nile-Red-O at RT
and in the dark. After washing 2 times with PBS, cells were
scanned using the Thermo Scientific Cellomics® ArrayScan®
VTI. vHCS™:View software was used to determine the average
Nile Red O intensity per DAPI-positive cell. Images were taken
using an EVOS fl fluorescent microscope (Advanced Micro-
scope Group, Mill Creek, WA, USA).
Chondrogenic differentiation
Pellets of 250,000 BMSCs were formed by centrifugation of the
cells produced by the individual clonal strains for 5 min at
1500 rpm in round bottom ultra-low attachment 96-wells
plates (Corning, NY, USA). The pellets were maintained in
chondrogenic differentiation medium at 37 °C and 5% CO2. The
medium contained high glucose DMEM (Invitrogen) supplement-
ed with 1% ITS + premix (BD Biosciences, Belgium), 10−7 M
dexamethasone (Sigma), 0.2 mM L-ascorbic acid 2-phosphate
(Sigma), 100 units/ml penicillin and 100 mg/ml streptomycin
(Invitrogen), and 10 ng/ml TGF-β2 (R&D Systems). Themedium
was refreshed twice each week. After a period of 4 weeks
the cell pellets were processed for histology (n = 2) and for
quantitative glycosaminoglycan (GAG) analysis (n = 3).
Quantitative analysis of glycosaminoglycans
Quantification of sulfated GAG in the pellets was performed
using the 1,9-dimethyl-methylene blue (DMMB; Sigma) assay
as described previously (Farndale et al., 1986). Briefly,
pellets were digested overnight at 60 °C in 250 μg/ml
papain buffer (Sigma) with 0.2 M NaH2PO4 (Merck), and 0.01 MEDTA (Sigma). Reference samples of known concentrations of
chondroitin-6-sulfate were prepared. DMMB staining solution
(46 μM DMMB, 0.04 M NaCl, 0.04 M glycine; all from Sigma)
was then added to the samples and standards. Absorbance
was measured at 540 and 595 nm on a 96-wells plate reader
(Bio-Rad). Concentrations of GAG were calculated by taking
the ratio of absorbances at 540/595 nm and based on a
second degree polynomial fit of the standard curve. The
amount of GAG per pellet was normalized to the total amount
of DNA per pellet. Total DNA was assessed in digested
samples using a Quant-iT PicoGreen dsDNA kit according to
manufacturer's instructions (Molecular Probes, Invitrogen).
(Immuno)histochemical staining
Pellets were fixed in formalin, embedded in paraffin and
5 μm sections were cut. After deparaffinization and rehy-
dration safranin-O staining and collagen type II immunohis-
tochemistry were performed on three sections per pellet.
Sections were first stained in Weigert's hematoxylin (Klinipath
BV) to detect cell nuclei and subsequently in 0.4% fast green
(Merck). Next, proteoglycans were detected with 0.125%
safranin-O (Merck) before dehydration and mounting in
DePex. For detection of collagen type II, antigen retrieval
was carried out by incubating with 1 mg/ml pronase and
10 mg/ml hyaluronidase (both from Sigma). Subsequently,
tissue sections were blocked in 0.3% H2O2 and in 5% bovine
serum albumin in PBS, followed by incubation with the
primary antibody recognizing specific collagen type II (1:100,
II-II6B3, Developmental Studies Hybridoma Bank) overnight
at 4 °C. A secondary goat anti-mouse antibody, conjugated
with horse radish peroxidase (Dako, Denmark), was applied
at RT for 1 h in a 1:200 dilution and antibody binding was
detected by incubation with 3,3′-diaminobenzidine tetrahy-
drochloride hydrate (DAB; Sigma) for 10 min. Finally, cell
nuclei were counterstained with hematoxylin and sections
were mounted. Isotype control staining was performed by
replacement of the primary antibody with mouse isotype
IgG1 monoclonal antibody (Friedenstein et al.) at matching
concentrations.
Cell surface marker expression of single colony-
derived BMSC cultures
Passage 3 BMSCs were analyzed for antigen expression profile
using monoclonal antibodies (mAbs) against human cell sur-
face markers. For direct conjugated antigen expression
studies 3 × 104 cells were washed with PBS and stained with
specific monoclonal antibody or isotype controls for 30 min on
ice in the dark. For indirect immunofluorescence, cells were
washed twice after specific first labeling and subsequently
incubated for 30 min with mouse secondary antibodies on ice
and in the dark. Samples were washed and analyzed in a
FACSCanto flow cytometer (Abdallah & Kassem, 2008) with BD
FACSDiva™ software. The mAbs used for immunophenotyping
were as shown in Supplemental Table 1.
Statistical analysis
Data were presented as mean ± standard deviations.
Spearman's rank correlations were used to determine
correlations between the cumulative CFU-F, cell numbers
Clone 1:
13.8%
Clone 8:
5.4%
Clone 38:
0.1%
Clone 42:
0.2%
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432 H-J. Prins et al.and in vivo bone formation. To determine the ability to
distinguish between clones with and those without bone
forming capacity, a Receiver Operating Characteristic (ROC)
curve was made using GraphPad Prism 4, and the area under
the curve (AUC) was calculated. ROC curve is a widely used
standard method to compare the accuracy of a diagnostic
test. It represents the tradeoff between false negative and
false positive for every possible cutoff. A higher area under
the curve (AUC) for a given parameter indicates a higher
probability of this parameter to predict for in vivo bone
forming capacity. A test was considered statistically signifi-
cant when the p-value was less than 1%. Correlations between
variables were assessed by Spearman's rank correlation
coefficient. Significant differences between clones for GAG/
DNA datawere analyzed by ANOVA and a Bonferroni correction
in SPSS 15.0.Clone 32:
37.7%
B Clone 1:
4.4% Clone 8:
1.8%
Clone 32:
76%
Clone 38:
0.1%
Clone 42:
0.3%
Figure 1 Cumulative cell counts and colony numbers. The
theoretical cumulative total cell production and number of
generated colonies for each individual clone were calculated
and the relative contribution of each individual clone depicted
as the percentage of the total cell production (A) and generated
colonies (B). The percentages are shown only for the clones with
in vivo bone forming capacity.Results
Heterogeneity in proliferation of the clonal
BMSC cultures
To investigate the heterogeneity within BMSC cultures, we
isolated clonal BMSC strains from human BM by seeding 10,000
mononuclear BM cells per well in seven 96-wells plates. Out-
growth of single BMSC colonies from the adherent cell fraction
was observed in 50 out of 672 seeded wells, indicating a
frequency of one colony per 134,400 cells. The low frequency
of 7% of the wells with cell growth is in agreement with the
assumption that only one clonogenic cell was present in these
wells. Moreover, we did not observe outgrowth of more than
one CFU-F per well. A total of sixteen of the 50 clonal BMSC
cultures could be expanded through passage three to produce
sufficient cells for further characterization.We calculated the
cumulative colony forming efficiency and total cell production
per clone after passage four as a percentage of the total
cumulative CFE and total cell number of the sixteen selected
clones. These differed approximately 100-fold between clone
38 which had the lowest proliferative capacity of 2.3 × 107
and clone 32 which had the highest proliferative capacity of
2.0 × 109 cells. The cumulative number of colonies that could
be generated from these sixteen clones differed more than
7000-fold, ranging from 2.3 × 104 colonies for clone 12 to
1.7 × 108 colonies for clone 32. The relative contribution of
each individual clone was calculated and depicted as the per-
centage of the total cell production (Fig. 1A) and generated
colonies (Fig. 1B). The percentages are shown only for the
clones with in vivo bone forming capacity. Spearman's rank
correlations showed a statistically significant correlation
between the cumulative number of colonies and the cumula-
tive number of cells (Spearman r = 0.77; p b 0.01). These data
demonstrate the heterogeneity in proliferation capacity in
primary BMSC clones derived from the same donor.Heterogeneity of in vivo bone formation of the
clonal BMSC cultures
Using an in vivo model for bone formation (Groen et al.,
2012; Prins et al., 2009; Siddappa et al., 2007, 2008), bone
forming capacity was demonstrated for five of the sixteenclones. Of these, clone 8 showed the most extensive bone
forming capacity (13.1%) while clone 42 only showed minimal
bone formation (Figs. 2A, B), and eleven of the sixteen clones
did not show any in vivo bone forming capacity (Fig. 2A). The
bone that is deposited on the scaffold material contained
embedded osteocytes as well as a prominent layer of osteo-
blast (Fig. 2B). We did not find a correlation between the
percentage of bone formation and the cumulative colony
numbers, (Spearman r = 0.36; p = 0.16), indicating that the
formation of secondary and tertiary colonies is not a predictor
for in vivo bone formation.
Cell surface marker expression
To investigate if a cell surface marker could predict in vivo
bone formation, we determined the immunophenotype of
the cultured BMSCs using mAb staining and flow cytometry
analysis. More than 90% of the cells of all clonal strains
Figure 2 In vivo bone formation. In vivo bone formation was
tested in an ectopic murine immune-deficient model. (A) The
average percentage of bone per pore available space for each
individual clone. X indicates no in vivo bone formation. (B)
Representative histological sections of bone formation by BMSCs
from clone 8 (left) and clone 42 are shown at increasingmicroscopic
magnifications (original magnification 25×, 100×; 400× from top to
bottom). Scaffoldmaterial is shown in gray/black (S), newly formed
bone is basic fuchsin-stained pink. The bone lining the scaffold
contained embedded osteocytes (Oc) and a prominent osteoblastic
(Ob) layer on the luminal surfaces. Connective tissue (Ct) was
present between and around the scaffolds.
433In vitro induction of ALP levels predicts in vivo bone forming capacity of human BMSCsexpressed the recognized BMSC markers CD73, CD90, CD13,
CD105, CD166, CD63, CD29, CD49e, CD44, CD71, CD146,
HLA-ABC, and β2-microglobulin and lacked expression (b1%)
of HLA-DR and hematopoietic markers, including CD3, CD19,
CD34, CD45, CD117 (Supplemental Table 1). The markers
identifying BMSC subpopulations with variable expression
between the clones (1–90%) were considered to be the mostpromising to identify cells with bone forming capacity.
These include the monocyte marker CD14, the endothelial
marker CD31 (PECAM-1), the decay-accelerating factor CD55,
the erythroid marker glycophorin A (CD235a), the low-affinity
nerve growth factor receptor (CD271), the neural ganglioside
GD2 (NG-GD2), the stromal cell precursor marker in human
bone marrow Stro-1, the stage-specific embryonic antigen
4 (SSEA-4), a mAb recognizing subpopulations of BMSC and
neural progenitor cells (W4A5) and tissue non-specific alkaline
phosphatase (TNAP/MSCA-1)(Supplemental Table 1). The re-
sults of the membrane marker expression analysis once more
showed that there is substantially more heterogeneity in BMSC
cultures than is generally recognized. None of the markers
however, correlated with or were predictive of in vivo bone
formation.Induction of ALP predicts in vivo bone formation
Third passage clonal BMSC strains were differentiated
towards the osteogenic lineage and at day one, and after
seven and 11 days of differentiation, ALP enzymatic activity
was analyzed and quantified as mean ALP activity per cell
using the Thermo Cellomics® ArrayScan® VTi. Remarkable
differences were observed in the absolute amounts of ALP
activity per cell for the clones at day one (Fig. 3A). Some of
the clones showed an increase of ALP activity at day seven
and/or day 11 upon differentiating the cells towards the
osteogenic lineage, whereas other clones did not (Fig. 3B).
Following normalization of ALP levels to day one, ALP
activity fold-induction ranged from a 1.1-fold increase to a
5.5-fold increase at day 11 (Fig. 3B). We performed ROC
analysis to determine whether ALP activity could serve as a
marker to identify clones with in vivo bone forming capacity.
This analysis is a widely used standard method to compare
the accuracy of a diagnostic test (Mentink et al., 2013). It
represents the tradeoff between false negative and false
positive for every possible cutoff. A higher area under the
curve (AUC) for a given parameter indicates a higher
probability that this parameter will predict for in vivo bone
forming capacity. A test was considered statistically signif-
icant when the p-value was less than 1%. A diagnostic test
always has false positive and negative results. The AUC of
N0.93 that we observed, indicates a very high probability of
ALP induction to predict for in vivo bone formation and
implicates that the level of induction of ALP activity during
in vitro osteogenic differentiation has a high probability to
predict for in vivo bone formation (p b 0.01) (Fig. 3C).
To extend our observation that induction of ALP activity
could serve as a predictive parameter for in vivo bone
formation, we analyzed ALP mRNA levels using qRT-PCR
(Fig. 3D). For comparison, we also analyzed the mRNA ex-
pression of other known osteogenic markers including
collagen type Iα1 (Col-Iα1), non-collagenous proteins of the
extracellular matrix such as osteocalcin (OC), osteonectin
(ON), osteopontin (OP), and bone sialoprotein (BSP), and the
bone-related transcription factor Runx2. mRNA expression
levels were determined during osteogenic differentiation at
days seven and 11. Table 1 shows the AUC for ROC curves and
associated p value for the markers tested. We typically
observed that OC, Runx2 and BSP mRNA levels increased
progressively during osteogenic differentiation for the clones
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Figure 3 Alkaline phosphatase expression and induction in clonal BMSC strains. The ALP activity was determined using a fluorescent
ALP substrate. Fluorescence was measured on a Cellomics ArrayScan VTI High Content Screening (HCS) platform and calculated per
DAPI-positive stained cell. Absolute values of alkaline phosphatase (ALP) activity are shown for each individual clone (A). ALP activity
was normalized to day 1 and depicted as ALP-fold induction after induction of osteogenic differentiation at day 7 and day 11 (B). The
ALP activity determined at mRNA level and the calculated fold-induction is depicted in (D). The probability of ALP induction as a
predictive marker for in vivo bone forming capacity was evaluated using a Receiver Operating Characteristic (ROC) curve for the ALP
activity level (C) and for the mRNA level (E). A completely random predictor would be given by a diagonal ‘line of no discrimination’
(dotted line).
434 H-J. Prins et al.that formed bone in vivo, whereas less increase was observed
in the clones that did not result in in vivo bone formation.
However, there was no statistical significance (p = 0.10; p =
0.06; p = 0.08, respectively), indicating that these markers
do not have a high probability of predicting in vivo bone
formation. Expression of ON, OP, and Col-1 resulted in values
reflecting more random predictions for in vivo bone forming
capacity (p = 0.53; p = 0.23; p = 0.19, respectively) implicat-
ing that there is no correlation between in vitro differentia-
tion and expression of ON, OP and Col-1. ALP mRNA induction
showed the highest AUC (0.95) and a p-value of b0.01
(Fig. 3E). This supports the data from the ALP activitymeasure-
ments, and suggests that for BMSCs in vitro changes in ALPexpression are highly predictive of in vivo bone forming
capacity.In vitro differentiation capacity of the clonal
BMSC strains
To evaluate the multi-potency of clonal BMSC cultures, cells
were also differentiated towards adipocytes and chondrocytes.
Cells from all 16 clones were differentiated towards adipo-
cytes for 14 days in specific differentiation media. Adipocyte
differentiation was defined by the appearance of Oil Red
O-positive stained lipid droplets after 14 days (Fig. 4A; Clone
435In vitro induction of ALP levels predicts in vivo bone forming capacity of human BMSCs28 is shown as an example). Quantification of the induction of
Nile Red-positive lipid containing droplets per DAPI-positive
cell (Fig. 4B) revealed an increase of the fluorescence for 11
from the 16 clones from 3.9 ± 0.5 to 1.1 ± 0.2 fold (Fig. 4C).
No Nile Red O-positive cells were detected in the uninduced
control cells. Cells from 14 of the 16 clones were also analyzed
for chondrogenic differentiation. Clones 12 and 34 could not
be included due to insufficient numbers of cells at passage
three. In vitro chondrogenesis was evaluated by safranin-O
and toluidine blue staining to detect GAGs, and staining for
cartilage-specific collagen type II. Positive staining for all
markers was only observed in clones 32 and 42 (Fig. 4D; E,
Supplemental Fig. Fig. 1) indicating the ability to differentiate
into chondrocytes. Quantification of the amount of sulfated
GAGs in the pellets revealed that only those from clones 32
and 42 produced significantly more GAG/DNA (N10) compared
to those of all other clones (Fig. 4F), which confirmed the
histological results. Lacunae resembling those surrounding
chondrocytes were evident in histological sections from clones
32 and 42 (Fig. 4E, Supplemental Fig. 1).
The differences in the capacity to differentiate towards
adipocytes and chondrocytes demonstrate the heterogene-
ity in multi-potency among the clones. The capacity to
differentiate to adipocytes or chondrocytes was not predic-
tive of in vivo bone formation.
The magnitude of induction of ALP is predictive of
in vivo bone forming capacity of non-clonal
BMSC cultures
To extend and confirm our initial observation that induction of
ALP levels during in vitro osteogenic differentiation in clonal
BMSCs predicts in vivo bone forming capacity, we analyzed the
induction of ALP during in vitro differentiation of total BMSC
cultures derived from different donors and correlated this to
the in vivo bone forming capacity of each non-clonal BMSC
culture. Previously we characterized and reported the in vivo
bone forming capacity of several BMSC cultures from different
donors (Prins et al., 2009), and we now measured induction of
ALP activity during in vitro differentiation. BMSCs that showed
a lowmagnitude of induction (b5.2 fold) of ALP activity at day
11 of in vitro osteogenic differentiation did not form bone
in vivo (Fig. 5). However, BMSCs that showed a highmagnitude
of induction (N8.2 fold) of ALP activity at day 11 of in vitro
osteogenic differentiation were successful in generating bone
in vivo (Fig. 5). These data extend and confirm the data
obtained with the BMSC clones and show that ALP induction in
non-clonal BMSC strains is also predictive of in vivo bone-
forming capacity.
Discussion
Our study on the characteristics of clonally expanded BMSC
cultures strongly supports the postulate that there is a large
degree of heterogeneity in BMSC cultures, not only on the
basis of in vitro parameters for characterization, but also
when using the in vivo test for functional bone forming
capacity. Previous in vitro studies have shown heterogeneity
in BMSC cultures (Digirolamo et al., 1999) (Colter et al.,
2000; Colter et al., 2001; Sekiya et al., 2002; Smith et al.,
2004), however, until now, a specific marker profile for cellswith specific differentiation properties has not been described.
Our study shows that single colony-derived clonal BMSC strains
derived from the same donor exhibit a broad in vitro pro-
liferation and differentiation profile and this was extended to
in vivo bone formation. The most rapidly proliferating single
colony-derived stromal cell culture in our study (clone 32;
Fig. 1) is composed of cells with the highest differentiation
capacity. The cells showed potential to differentiate into
the osteogenic, adipogenic and chondrogenic lineages as well
as to form bone in vivo in substantial amounts (Figs. 2, 4C, F;
Table 2).
Only a limited number (31%) of single colony cultures
exhibited in vivo bone forming capacity. These observations
are in line with a previous report by Kuznetsov et al., who
showed that a similar proportion, (33.3%), of clonally derived
human marrow stromal fibroblasts (which he defined as
“strains”), established from different donors, exhibited in vivo
bone forming potential (Kuznetsov et al., 1997). The accurate
selection or identification of clones with in vivo osteogenic
capacity would benefit patient treatment for osteogenic
defects. Therefore, we investigated several parameters that
might be utilized to predict in vivo osteogenic capacity. Neither
the number of cells produced per initial CFU-F nor the colony
producing capacity was useful for predicting in vivo bone
forming capacity.
Our data indicate that the large variability between
donors can be explained by the composition and properties
of a given clonal mixture from the primary isolated BMSCs.
This clonal mixture consists of several populations among
which are multi-potent stem cells, committed progenitors,
lineage restricted cells, and senescent cells. We showed that
2 of 16 clones were multi-potent and able to differentiate
into osteoblasts as well as chondrocytes and adipocytes; 4 of
16 clones were bi-potent and able to differentiate into
osteoblasts as well as into adipocytes; 7 of 16 clones were
uni-potent and their differentiation potential was restricted
to either the adipocytic or osteogenic lineage; 3 of 16 clones
were not able to differentiate into any of the three lineages.
A most striking observation was that the chondrocytic
differentiation potential was only observed in combination
with adipocyte and osteoblast potential, suggesting a hierar-
chy in differentiation potential (Pittenger et al., 1999; Russell
et al., 2010). From the seven clones with in vitro osteogenic
potential, only five also exhibited in vivo bone forming
potential (Table 2). These phenomena might explain why the
first attempts to generate osteogenic grafts with human
BMSCs were unsuccessful in standard clinical application
(Goldstein et al., 1999) (Meijer et al., 2007; Quarto et al.,
2001; Schimming and Schmelzeisen, 2004; Schultz et al.,
2000; Ueda et al., 2008). In an attempt to identify a surface
marker that could distinguish between cells with and without
in vivo bone forming capacity, we evaluated our clonal BMSC
strains for several previously reported cell surface markers
using flow cytometry. Some of these markers were included as
they are known to react with specific subpopulations within
the CFU-F fraction in freshly collected BM (Aslan et al., 2006;
Baksh et al., 2007; Battula et al., 2008; Deschaseaux et al.,
2003; Gang et al., 2007; Groen et al., 2011; Majumdar et al.,
2000; Martinez et al., 2007; Rider et al., 2007; Rozemuller et
al., 2010; Sacchetti et al., 2007; Simmons and Torok-Storb,
1991; Sobiesiak et al., 2010; Sorrentino et al., 2008; Stewart
et al., 2003; Tormin et al., 2009; Vogel et al., 2003). We
436 H-J. Prins et al.observed that BMSCs derived from single clones exhibit a
variable expression of several markers (Supplemental Table 1).
However, we could not find a single marker with a sufficiently
strong positive or negative correlation to identify the clones
with in vivo bone forming capacity. The heterogeneity in the
reactivity profiles of the mAbs that we used lends support to
the concept that subpopulations in the BM as well as culturedBMSCs exist and it opens the possibility to use multiparameter
flow sorting to identify a specific BMSC subfraction with in vivo
bone forming potential.
All the potential markers and parameters discussed above
failed to correlate with the capacity of the clonal derived
BMSCs to form bone in vivo. However, in our analysis of
clonally-derived BMSC strains, we identified a novel
Figure 5 Fold ALP induction of in vitro osteogenic differentiation and in vivo osteogenic differentiation of BMSCs. Fold induction of
ALP levels during in vitro osteogenic differentiation at days 7 and 11 of total BMSC populations of different donors compared to in vivo
osteogenic differentiation capacity (+ or −) of the same donors. D29, D32, D93, D03, D06, D99 and “multi-colony” are the different
donors and “multi-colony” is the same donor the clonal MSC strains were derived from.
437In vitro induction of ALP levels predicts in vivo bone forming capacity of human BMSCsparameter that can predict the in vivo differentiation capacity
of BMSCs: induction of ALP mRNA and activity levels. We
showed that induction of ALP levels (Figs. 3B, C) but not the
initial levels of ALP (Fig. 3A) is highly predictive for the in vivo
osteogenic differentiation capacity of these clones (Fig. 2A).
Moreover, we confirmed our observations by using total
BMSC preparations derived from different donors. Analysis of
these strains and the original clonal strains showed a 100%
correlation between in vivo bone forming capacity and ALP
induction during in vitro osteogenic differentiation (Fig. 5).
ALP enzyme activity is increased in the early stages of
osteoblast commitment and upregulation of ALP activity
during osteogenic differentiation is assumed to reflect the
number of osteogenic committed progenitor cells in a cell
population. High variations in ALP levels and in in vitro
induction kinetics that differentiate between human BMSC
donor populations have previously been reported (Phinney
et al., 1999) (Jaiswal et al., 1997).We found a novel correlation
between the degree to which ALP activity of a given clone
could be induced and the in vivo bone forming capacity, both
at the mRNA level as well as in enzyme activity (Figs. 3C, E).
We showed that, upon differentiation of the clonally-derived
BMSCs towards the osteogenic lineage, ALP induction of more
than two-fold and mRNA induction of more than four-
fold after 11 days of differentiation predicts the capacity for
in vivo bone forming capacity in 14 of 16 clones. The clonal
BMSCs with in vivo bone forming capacity also displayed the
lowest ALP levels at the onset of the differentiation assay as
compared to those without in vivo bone forming capacity,
indicating that high ALP levels in BMSC cultures, while
suggesting in vivo bone forming capacity, in fact anticorrelate
with in vivo bone forming capacity. Moreover, we extended
our observations to non-clonal BMSC populations and showedFigure 4 Adipogenic and chondrogenic differentiation. Differentia
lipid-rich vacuoles within the differentiated cells. Lipid vacuoles
magnification 200×) and quantification was performed after fluoresc
(B; scale bar = 400 μm). Nile Red O staining at day 14. X indicates no
pellets were stained for cartilage-specific collagen type II by immun
collagen expression in the extensive extracellular matrix. Pellets we
E), Chondrocyte-like lacunae are evident in histological sections fro
sulfated glycosaminoglycans (GAGs) analysis (n = 3). The GAG conte
between clones for GAG/DNA are considered to be significant whe
counterstained with hematoxylin, staining the nuclei blue (E).that from seven donors, four donors showed a high induction of
ALP during in vitro differentiation (N8.2 fold, 11 days), which
correlated fully with the in vivo bone forming capacity of
these donors. Three of the seven donors did not show a high
magnitude of induction of ALP during in vitro differentiation
and here we could not detect any in vivo bone formation. A
possible relationship between in vitro ALP induction and
in vivo bone forming capacity has been previously suggested
(Mendes et al., 2004; Siddappa et al., 2007). The discrepan-
cies between the thresholds of ALP induction during in vitro
differentiation of the clonal BMSC strains and the non-clonal
BMSC populations and in vivo bone forming capacity could
perhaps be explained by the higher number of population
doublings of the clonal BMSC strains and their gradual
subsequent loss of response to in vitro osteogenic stimuli
(Siddappa et al., 2007). Inclusion of control cells during
in vitro osteogenic differentiation would allow controlling
for differences between experiments and would be benefi-
cial in determining a threshold that could be used for the
selection of BMSCs with in vivo bone forming capacity.
Although the same scaffolds were used throughout our
study to determine the in vivo bone forming capacity, the type
of material and composition of the scaffold do affect some
of the in vivo properties of BMSCs (Yuan et al., 2010). The
formation of bone tissue and bone marrow like structures,
blood vessels and hematopoietic cells therein can vary
depending on the scaffold used. The use of a different
substrate or scaffold could induce the cells into a different
lineage (Engler et al., 2006) (Dupont et al., 2011).
The generation of osteogenic grafts with human BMSCs
for clinical application requires cells with in vivo osteogenic
potential. Since prolonged culturing of cells reduces the
osteogenic potential (Siddappa et al., 2007) of BMSCs, antion to adipocytes was verified by staining the accumulation of
were stained using Oil Red O for visual inspection (A; original
ent Nile Red O staining; nuclei were counter-stained using DAPI
adipogenic differentiation (C). For analyses of chondrogenesis,
ohistochemistry using a specific antibody (D) showing the type II
re stained for glycosaminoglycans by safranin-O staining (n = 2;
m clones 32 and 42 (E). Pellets were harvested for quantitative
nt of the pellets is expressed as GAG per DNA (F). Differences
n p b 0.01 and are marked with an asterisk (*). Sections were
Table 2 Multi-differentiation potential. The clones that
displayed the capability to be differentiated towards
adipocytes (A), osteoblasts (O), chondrocytes (C) and/or
form in vivo bone (B), are marked with X. NA = not analyzed.
Clone A O C B
1 X X X
2 X
7
8 X X X
11 X
12 NA
28 X
30 X X
32 X X X X
33
34 X NA
37 X
38 X X
42 X X X X
44 X
45 X X
438 H-J. Prins et al.alternative procedure would be to directly load BMSCs on
scaffolds such as has been proposed by the group of Martin
(Di Maggio et al., 2011). They showed that prolonged perfusion
of, in this case total bone marrow, and immediate implanta-
tion resulted in in vivo bone formation. However, for large
scale scaffold loading it might be more efficient to increase
the frequency and thereby increase the total number of BMSC
with bone forming capacity by concentrating the BMSC based
on their CD marker profile.
So far, prospective markers to isolate or identify the
BMSC population with in vivo osteogenic potential have been
scarce and with limitations, but it has been described that
sorting for CD271, CD56, MSCA-1 and MSCA-2 (Battula et al.,
2008) (Rozemuller et al., 2010), CD146 (Sacchetti et al.,
2007), CD90 (Chung et al., 2013) and ALDH (Gentry et al.,
2007) results in enrichment of BMSC with multipotent
capacity, including in vivo bone formation. Recently, Larsen
et al. identified decorin, lysyl oxidase-like 4, natriuretic
peptide receptor C, and tetranectin as being upregulated in
cells that are osteogenic in vivo by comparing low versus
high bone forming hMSC-TERT cell populations (Larsen et al.,
2010). However, in this study the identified molecular
phenotype was not tested in total BMSC cultures from
primary bone marrow cells from different donors. The
results from our study could explain the fact that in their
study a positive correlation for ALP levels was not found,
since we demonstrated that induction of ALP levels (and
not necessarily the actual level of ALP) is predictive for the
in vivo osteogenic differentiation capacity.
Finally, our data show that an in vitro osteogenic differentia-
tion capacity parameter can be used to classify produced
clinical BMSC batches for the best in vivo osteogenic potential
within twelve days. Despite the heterogeneity within BMSC
cultures and between cultures from different donors, the
magnitude of ALP induction during in vitro osteogenic dif-
ferentiation predicts the in vivo osteogenic differentiation
capacity for most of the cases that we studied and will aid inthe selection of the optimal BMSC population for use in
patients. Our findings should be taken into consideration when
developing clinical protocols that aim at generating BMSCs for
the engineering of human bone.Author disclosure statement
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